Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date of submission: February 18, 2019

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, BandraKurla Complex Mumbai – 400 050 Scrip Code- BIOCON

Dear Sir/Madam,

Sub: Biocon Facilities complete Pre Approval U.S.FDA Inspection
Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

"This is to inform you that the U.S.FDA concluded two pre approval inspections of Biocon's manufacturing facilities in Bengaluru.

There were no observations and no Form 483 was issued after the pre-approval inspection of our Oral Solid Dosage Facility conducted between 11th-15th Feb 2019.

The pre-approval inspection of our additional, new injectable manufacturing line for a biologic drug product, conducted between 7th-15th Feb 2019, resulted in a form 483 with two observations. Biocon intends to address these expeditiously.

We remain committed to global standards of Quality and Compliance." – ***Company Spokesperson***

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Satish Kumar SS
Company Secretary and Compliance Officer